Roche Tocilizumab IP Relaxation Does Not Go Far Enough
MSF Says Non-Enforcement Of Actemra/RoActemra Patents Should Go Beyond LMICs
After the WHO recommended the use of IL-6 receptor blockers to treat patients hospitalized with severe or critical COVID-19, Actemra/RoActemra originator Roche pledged not to enforce IP covering the tocilizumab brand in low- and middle-income countries during the pandemic. But humanitarian organization MSF says this does not go far enough.
